现在主要药品的专利权马上要过期,就要面对仿制药的挑战。而新药品的研发渠道里看不到好的新药上市。所以他们高价兼并了一家有新药的企业,但是投资者都认为代价太大。
现在主要药品的专利权马上要过期,就要面对仿制药的挑战。而新药品的研发渠道里看不到好的新药上市。所以他们高价兼并了一家有新药的企业,但是投资者都认为代价太大。
WENXUECITY.COM does not represent or guarantee the truthfulness, accuracy, or reliability of any of communications posted by other users.
Copyright ©1998-2025 wenxuecity.com All rights reserved. Privacy Statement & Terms of Use & User Privacy Protection Policy